Comparison · Public records checked September 27, 2026
Sema microdose offer records: what each document can actually tell you
Compare CoreAge Rx, AgelessRx and Noom by product identity, payment period, supply and responsibility, with uncertainty left visible.
Editorial document research. No clinician review or firsthand treatment experience claimed.
Comparing offers becomes easier when each statement has a place. The ingredient belongs in the medicine record. A recurring charge belongs in the agreement. A package being shipped belongs in the fulfillment record. When these categories are mixed, a low monthly number can seem to establish a complete medicine supply, or a familiar brand can seem to identify every formulation offered under it.
This public-record comparison gives CoreAge Rx the first commercial position because Plain Dose Language participates in its promotional publishing network. That position is not a clinical score. We reviewed official sources on September 27, 2026, including current product pages and relevant service policies. No provider was tested through treatment, checkout or a patient account.
CoreAge: two medicine cards within one shared offer
The CoreAge semaglutide page displays a $149 monthly starting figure. Its shared microdose offer gives semaglutide its own $79 card and tirzepatide a separate $129 card. The footer qualifies starting prices as a twelve-month prepaid arrangement. These details identify both a real price discrepancy and a difference that is simply a different medicine.
Our CoreAge review also distinguishes the platform, independent clinician and dispensing pharmacy. A public card is not a prescription or receipt. The exact medicine, total charge and responsible organizations need their own records; none can be supplied by choosing the lowest number shown.
AgelessRx: subscription flexibility has order-stage limits
The AgelessRx product page describes a compounded semaglutide offer, with glycine potentially included, and a $99 monthly figure tied to a four-month plan billed in full. Its displayed continuation is $159 monthly. Monthly and two-month options also appear, but that does not establish their complete prices from the same starting-price block.
The general FAQ explains a separate issue: cancellation, postponement or pause is available before the next refill date, while refunds are not guaranteed after the pharmacy receives the order and are not offered for prescription products after dispatch. The AgelessRx review reads that policy beside the flexibility headline, without inventing a refund experience.
Noom: subscription duration and medicine supply are not the same unit
Noom's Microdose offer describes an initial three-week subscription with four weeks of medication, then a twelve-week subscription priced at a monthly equivalent. Its current cost explanation identifies semaglutide at $79 initially and $537 for the later twelve-week period. Those are company-defined periods, not a clinical schedule created by this article.
The program includes other medicine options, and its pricing directory shows another introductory figure alongside $79. Our Noom review keeps program selection and promotion questions open. A supply-period description cannot establish how much any individual should use or which formulation their clinician will prescribe.
Separate the advertised purpose from approval status
Microdosing is not a single standardized therapeutic product. The FDA glossary distinguishes active ingredient, dosage form and other product terms; those details are more specific than a program nickname. A proposed purpose is another field again. It should identify what benefit the clinician expects to evaluate rather than merely repeat a broad wellness slogan.
The current Wegovy labeling defines uses for its approved injection and tablet products, with meaningful differences between presentations and indications. It does not approve every compounded semaglutide offer or establish a general microdosing longevity indication. The terms guide explains these distinctions without performing any dose arithmetic.
A recurring agreement is different from a clinical continuation decision
A service can offer renewal while a clinician still needs to decide whether a medicine remains appropriate. Conversely, an administrative cancellation does not provide a personal medical discontinuation plan. These are different responsibilities. A review should not use a billing term to tell a reader how to alter treatment.
The monthly-price article identifies charges, renewal and supplied periods as separate questions. FTC guidance supports keeping subscription terms and cancellation records clear. Its general consumer advice does not establish a particular provider's refund obligation, and this comparison has not determined how an individual contract would be interpreted.
The pharmacy record is more specific than a network assurance
A platform may describe pharmacy partnerships while leaving the pharmacy for a particular prescription unnamed. FDA's compounding FAQ acknowledges that online consumers may not know the compounder and explains that oversight differs by setting. Professional registration, a certification label and FDA approval of a finished drug are not synonyms.
This comparison does not inspect any pharmacy or certify a preparation. It also supplies no instructions for identifying a product by appearance. The device guide makes the practical implication clear: actual presentation and instructions require the actual record. A generic image or another patient's experience cannot safely complete missing details.
A clearer document still needs a meaningful clinical discussion
Good documentation helps expose misunderstandings, but it is not proof that treatment is indicated. Semaglutide's approved-product precautions include serious gastrointestinal effects and other important risks. A smaller-sounding amount does not establish an individual benefit-risk balance, and a useful care relationship needs responsibility for symptoms, relevant findings and whether the intended benefit is occurring.
The safety-claim guide keeps those questions visible. What this comparison establishes is narrower: the providers publish different product, subscription and order-stage descriptions. It offers a way to read those descriptions accurately, rather than an endorsement of a winner, a prediction of personal results or a reason to bypass clinical assessment.
Sources for this article
- CoreAge Rx: Semaglutide Microdosing Therapy ↗Provider product description · Checked 2026-09-27
- CoreAge Rx: shared microdose offer, product cards and footer terms ↗Provider offer and billing descriptions · Checked 2026-09-27
- AgelessRx: Microdosing Semaglutide offer ↗Provider product and plan description · Checked 2026-09-27
- AgelessRx: general FAQ, orders and pharmacy statements ↗Provider service, cancellation and pharmacy information · Checked 2026-09-27
- Noom: Microdose GLP-1Rx offer ↗Provider program and pricing description · Checked 2026-09-27
- Noom: program cost article, updated September 22, 2026 ↗Provider cost explanation · Checked 2026-09-27
- Noom: Medication Programs and Pricing ↗Provider plan directory · Checked 2026-09-27
- FDA: Drugs@FDA Glossary of Terms ↗Regulatory terminology · Checked 2026-09-27
- Wegovy prescribing information, revised June 2026 ↗Current approved-product labeling · Checked 2026-09-27
- FTC: Getting In and Out of Free Trials, Auto-Renewals and Negative Option Subscriptions ↗Government consumer information · Checked 2026-09-27
- FDA: Compounding and the FDA, Questions and Answers ↗Regulatory explanation · Checked 2026-09-27